Overview

Continuous Subcutaneous Infusion of Pramlintide and Insulin

Status:
Completed
Trial end date:
2007-11-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see if giving the study drug in a slow and steady dose will lower blood sugars during the meal and after-meal time.
Phase:
Phase 4
Details
Lead Sponsor:
Baylor College of Medicine
Treatments:
Islet Amyloid Polypeptide
Pramlintide